Literature DB >> 19930423

High-density lipoprotein: a potent inhibitor of inflammation.

Andrew J Murphy1, Kevin J Woollard.   

Abstract

1. Inflammation is an important process, driving the progression of atherosclerosis. Stemming inflammation may be a mechanism to inhibit the progression of this disease. 2. High-density lipoprotein (HDL), a particle inversely related to cardiovascular disease, has been described as having a number of anti-inflammatory functions. It has been shown that HDL inhibits endothelial inflammation in both in vitro and in vivo models, reducing the expression of key cell adhesion molecules. In addition, HDL has been shown to have an effect on the coagulation pathway by inhibiting platelet activation and reducing thrombus formation. Furthermore, by reducing the activation of leucocytes, HDL can inhibit leucocyte recruitment to the endothelium. 3. High-density lipoprotein infusion studies conducted in patients with inflammatory diseases have shown that acute treatment with HDL can effectively inhibit inflammation in vivo. Thus, HDL has been proven to be a potent inhibitor of inflammation, acting on a number of pathways, and this may suggest that HDL could be applied as an anti-inflammatory molecule for a number of diseases. 4. The present review highlights these important studies and reviews data on the anti-inflammatory effects of HDL from in vitro and in vivo studies, in both humans and animal models of atherosclerosis and inflammatory-related diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19930423     DOI: 10.1111/j.1440-1681.2009.05338.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  30 in total

Review 1.  Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells.

Authors:  Andrew J Murphy; Marit Westerterp; Laurent Yvan-Charvet; Alan R Tall
Journal:  Biochim Biophys Acta       Date:  2011-08-16

2.  Hypercholesterolaemia, signs of islet microangiopathy and altered angiogenesis precede onset of type 2 diabetes in the Goto-Kakizaki (GK) rat.

Authors:  M-H Giroix; J-C Irminger; G Lacraz; C Noll; S Calderari; J A Ehses; J Coulaud; M Cornut; N Kassis; F Schmidlin; J-L Paul; M Kergoat; N Janel; P A Halban; F Homo-Delarche
Journal:  Diabetologia       Date:  2011-07-10       Impact factor: 10.122

3.  Lipoproteins and lipoprotein metabolism in periodontal disease.

Authors:  Rachel Griffiths; Suzanne Barbour
Journal:  Clin Lipidol       Date:  2010-06

4.  HDL and Endothelial Function.

Authors:  Yufei Wu; Yangkai Xu; Jie Chen; Mingming Zhao; Kerry-Anne Rye
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Mild hypercholesterolemia blunts the proinflammatory and prothrombotic effects of hypertension on the cerebral microcirculation.

Authors:  Stephen F Rodrigues; Shantel A Vital; D Neil Granger
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-02       Impact factor: 6.200

6.  Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity.

Authors:  Jennifer H Madenspacher; Kathleen M Azzam; Wanghua Gong; Kymberly M Gowdy; Michael P Vitek; Daniel T Laskowitz; Alan T Remaley; Ji Ming Wang; Michael B Fessler
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157

Review 7.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

8.  Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts.

Authors:  Andrew M Cheng; Priya Handa; Sanshiro Tateya; Jay Schwartz; Chongren Tang; Poulami Mitra; John F Oram; Alan Chait; Francis Kim
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

9.  Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome.

Authors:  Gianna Ferretti; Tiziana Bacchetti; Simona Masciangelo; Graziano Grugni; Virginia Bicchiega
Journal:  Dis Model Mech       Date:  2012-07-19       Impact factor: 5.758

10.  Effect of Roux-en-Y Gastric Bypass on Lipoprotein Metabolism and Markers of HDL Functionality in Morbid Obese Patients.

Authors:  Ezequiel Lozano Chiappe; Maximiliano Martin; Andrea Iglesias Molli; Andrea Millan; Walter Tetzlaff; Eliana Botta; Florencia Ferraro; Maria S Sáez; Maria V Lorenzon Gonzalez; Laura Boero; Patricia Sorroche; Axel Beskow; Mercedes Gutierrez; Gloria Cerrone; Susana Gutt; Gustavo Frechtel; Fernando Brites
Journal:  Obes Surg       Date:  2020-10-30       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.